Revanesse is used in areas where short-term symptom management is appropriate. These products are applied when appropriate for adults to help address symptoms related to physical discomfort like moderate to severe facial wrinkles and to assist with volume restoration.

The treatment helps address symptom clusters related to structural changes, including static facial lines and deep folds, age-related facial volume depletion, and loss of lip definition and fullness. This assists in providing a smoothing effect on the skin's surface and is considered relevant for managing symptom clusters that may become intense or disruptive. This application generally contributes to easing the visible appearance of these lines and supports the patient's pursuit of a more balanced aesthetic.

“The treatment supports the patient's pursuit of a more balanced and aesthetically pleasing profile,” is relevant in contexts involving heightened systemic burden.

Quick Fact: Support for Volume Loss Revanesse supports the management of volume deficit in the mid-face and cheeks, which may assist with maintaining functional stability during symptomatic periods.

Eligibility and Contraindications for Revanesse Use

Revanesse is formally indicated for use only in adults 22 years of age or older; use in individuals under this age is not established and is contraindicated. Eligibility is strictly governed by regulatory labeling, which defines several absolute exclusions from treatment.

Absolute Contraindications

Use is prohibited for patients with a known history of severe allergies or anaphylaxis, or hypersensitivity to any component of the product, including Hyaluronic Acid, Lidocaine, or Streptococcal proteins. Patients with a history of keloid or hypertrophic scarring are excluded, as are those with active infections, unhealed wounds, or acute skin diseases (such as inflammatory acne or rosacea) near the intended injection site.

Population Restrictions

Revanesse should not be used in pregnant or nursing women, as the safety and effectiveness have not been established in these populations. Additionally, the product is contraindicated for individuals with bleeding disorders or those taking anticoagulant or antiplatelet therapy, due to an increased risk of bleeding. The official labeling also restricts its use in patients who have had recent procedures like a chemical peel or laser treatment (within 4 weeks).

Interactions with other medicines and products

Official regulatory documents define the interaction profile for this injectable dermal filler primarily through restrictions related to local tissue compatibility and co-administration timing.

Documented Interaction Categories

Interaction Type	Interacting Agents / Conditions	Regulatory Classification
Local Hemostasis	Anticoagulant and Antiplatelet medications (e.g., Warfarin, NSAIDs)	Use-with-Caution / Increased Local Risk
Local Dermal Response	Recent Laser, Chemical Peel, or Dermabrasion Procedures	Contraindicated Co-timing
Systemic Exposure	Strong inhibitors of Lidocaine metabolism (e.g., certain CYP inhibitors)	Potential Exposure Modification
Tissue Condition	Acute inflammation, skin infection, non-absorbable implants	Contraindicated Co-location

Official Interaction Statements

Co-administration with antiplatelet or anticoagulant agents is officially restricted due to a documented increased risk of localized bruising and bleeding at the injection site. This pharmacodynamic constraint also extends to certain herbal products, such as high-dose Vitamin E, Ginger, and Garlic, which may affect hemostasis.

Mandatory time separation is required between the filler injection and non-surgical dermal procedures like laser treatments; administration must be delayed until the treatment area is completely healed. Furthermore, the product is prohibited from being injected into any area exhibiting an active inflammatory process or previously treated with non-absorbable dermal implants. For formulations containing Lidocaine, caution is advised with medicines that could significantly inhibit its metabolism, potentially increasing its systemic concentration.

Revanesse is a non-pharmacologic injectable hydrogel, and its mechanism is primarily physiomechanical. The cross-linked hyaluronic acid (HA) formulation is exogenously deposited into the dermal or subdermal connective tissue space.

---

The HA biopolymer functions as a viscoelastic scaffold. At the molecular level, its highly hydrophilic nature dictates an osmotic interaction with surrounding tissue water, leading to the hydration and resultant expansion of the implanted matrix volume. This molecular property is translated into the system-level physiological consequence of mechanical tissue augmentation and spatial displacement of the extracellular matrix (ECM).

---

Over time, the exogenous HA undergoes hydrolytic degradation by native hyaluronidase enzymes. The degradation products are then metabolized via a natural catabolic pathway, resulting in the gradual, time-dependent regression of the initial mechanical effect. This process modulates the tissue's physical parameters by transiently increasing local pressure and inducing immediate volumetric enhancement of the targeted tissue plane.

Administration Overview

Revanesse is an injectable dermal filler composed of cross-linked hyaluronic acid. The application is performed by qualified healthcare professionals through a series of injections into the target areas of the face. The specific technique and depth of injection depend on the individual’s facial structure and the particular product within the Revanesse line being utilized.

The Procedure

Before the procedure begins, the skin is thoroughly cleansed and may be treated with a topical anesthetic to manage comfort. The healthcare professional then uses a fine-gauge needle or a blunt-tipped cannula to deliver the gel into the mid-to-deep dermis or the subcutaneous tissue.

During the session, the practitioner may gently massage the treated area to ensure even distribution of the gel and to achieve the desired contour. The duration of the procedure typically varies depending on the number of areas being addressed.

Post-Procedure Period

Following the injection, individuals can generally resume most daily activities. It is common for healthcare providers to suggest avoiding strenuous exercise, excessive sun or heat exposure, and the consumption of alcoholic beverages for a brief period. These measures help to manage the local inflammatory response.

Expected Results and Duration

The effects of the treatment are usually visible immediately after the session, though the final appearance is often best assessed after any initial swelling has subsided. The longevity of the results depends on several factors, including the specific area treated, the individual's metabolism, and the volume of gel used. Periodic maintenance sessions are typically required to sustain the aesthetic outcomes over time.

Research evidence / Overview of studies for Revanesse

Evidence for Use in Correction of Moderate to Severe Facial Folds

Controlled clinical research was studied for its application in measuring outcomes related to the appearance of static facial lines and deep folds, such as the nasolabial folds. Regulatory studies often involved randomized, multicenter, double-blind designs in which the product was evaluated alongside another approved dermal filler. The primary research approach was to examine findings derived from non-inferiority studies where the product was observed in relation to the active control.

These studies monitored outcomes related to physical discomfort and outcomes describing episodic or acute changes in the appearance of the folds. Research explored how the visible change was observed in adult populations 22 years of age or older who presented with moderate to severe wrinkles. Findings describe patterns observed in the studies at the 24-week mark, with long-term protocols continuing to track subjects for up to 52 weeks (one year).

Evidence for Use in Age-Related Mid-Face Volume Deficit

Research was evaluated in the context of volume loss in the mid-face, which is an outcome related to systemic or functional imbalance associated with age. The research examined the results from controlled clinical trials comparing the product (Revanesse Shape+) against other established fillers indicated for mid-face volume use. Studies explored how outcomes related to physical discomfort and change in volume were observed in adult patients between the ages of 22 and 65 who had age-related volume deficits.

What Remains Uncertain About the Research Base

The clinical research is primarily focused on non-inferiority studies, which means limited information is available regarding performance against non-treatment conditions. Furthermore, the follow-up durations were limited in many studies, and there is limited information for long-term outcomes beyond the one-year mark. Research highlights what is known — and what is still uncertain — regarding the longevity of the results and performance in various unstudied populations.

Common questions about Revanesse (FAQ)

Q: Is Revanesse FDA-approved for use around the eyes (tear troughs)?

The official FDA indications for Revanesse Versa+ are for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, and for lip augmentation. The specific use of the product in the periorbital area, such as the tear troughs, is not currently listed in the official regulatory labeling.

Q: Do results from Revanesse last longer in certain areas of the face compared to others?

Studies and official information indicate that the duration of any hyaluronic acid filler can vary depending on where it is injected. Areas that experience high muscle movement, such as the lips or around the mouth, may show a shorter duration of effect compared to areas of the face with less movement.

Q: What are the rare but serious risks associated with all hyaluronic acid fillers like Revanesse?

The most serious, though rare, risk cited across injectable dermal filler procedures is vascular occlusion. Potential consequences of this rare complication include the risk of skin necrosis (tissue death), blindness, and stroke. These risks are universally cited in the official safety information for dermal filler injections.

Q: Are there any known interactions between Revanesse and common skin treatments like laser or chemical peels?

Official regulatory guidelines state that use is contraindicated (prohibited) if the intended treatment area has not fully healed following non-surgical dermal procedures. This restriction is in place due to the potential for an exaggerated inflammatory reaction.

Q: Is Revanesse safe for individuals with specific autoimmune disorders?

Official regulatory documents list a history of certain connective tissue disorders, such as systemic lupus erythematosus, as a contraindication for the product’s use. Official guidelines indicate that increased consideration is needed for patients with any autoimmune condition.

Q: What kind of studies have been performed to assess the safety of Revanesse?

The safety and effectiveness are supported by evidence from controlled clinical trials. These studies are often designed as randomized, multicenter, double-blind trials and frequently follow a non-inferiority approach, comparing Revanesse against another approved dermal filler.

Q: Can Revanesse be dissolved or reversed if a patient is unsatisfied with the outcome?

Yes. Since the product is a hyaluronic acid filler, the material can be broken down by the injectable enzyme hyaluronidase in a medical setting. The availability of this enzyme is described as an essential safety feature for managing potential complications or addressing aesthetic concerns.

Q: What is the official recommended time interval for maintenance or touch-up treatments?

The official protocol defines the treatment as-needed, requiring follow-up procedures after the initial augmentation diminishes. The regulatory documents do not provide a fixed, specific time interval. The timing for maintenance is a decision made on an individualized basis as part of the established treatment protocol.

Q: What kind of adverse reactions have been reported weeks or months after treatment?

The official safety profile covers delayed adverse reactions, which may appear weeks or months after treatment. These less common reactions can include skin lumpiness (nodule formation), acne-like skin eruptions, and hyperpigmentation.

Q: Is there a maximum number of syringes of Revanesse that can be safely used in one session?

Administration is governed by a procedural dosing principle based on the required physical correction needed to meet the aesthetic goal. The official instructions for use do not specify a fixed maximum safe number of syringes for a single treatment session.

How to Store and Dispose of Revanesse?

Official regulatory documents define strict requirements for the storage, handling, and disposal of Revanesse to maintain product integrity and safety.

Storage/Handling Requirement	Official Constraint
Temperature	Store between 2 C and 25 C (Do not freeze).
Protection	Keep away from direct sunlight; keep dry.
Integrity	Do not use if the expiration date has passed or if the package is opened or damaged.
Reuse	Product is for single use only; do not reuse or resterilize the syringe and needle.

Used syringes and needles must be handled as potential biohazards and disposed of according to accepted medical practice and all applicable local, state, and federal requirements. These instructions ensure the product remains stable prior to use and is discarded safely afterward, minimizing risk.